Journal of Pakistan Psychiatric Society
March 3, 2023
Sawera Mansoor, Khalid Hayat Khan, Manzoor Ahmed Faridi
3 citations
Objectives: This study was conducted to evaluate the response of treatment resistant depression to IV ketamine therapy protocol and explore the perspectives of patients regarding the acceptability of this treatment modality. Study Design: Mixed methods assessment including Quasi experimental design and Qualitative interviews. Place and Duration of Study: The study was conducted at Department of...
Frontiers in Psychiatry
March 2, 2023
Hangyu Li, Wanli Qin, Nannan Li et al.
BackgroundAs a common clinical symptom, insomnia has a high incidence of combined mental illness and it is also a risk factor for the development of depression, anxiety and suicide. As a new concept in the field of health in recent years, mindfulness therapy can improve insomnia, anxiety and depression, which is a new way to solve such diseases.ObjectiveThis study aims to systematically...
European Psychiatry
March 1, 2023
Pierre A Geoffroy, Rodolphe Borand, Marine Ambar Akkaoui et al.
Introduction Sleep and circadian markers are of increasingly growing interest to help better predicting suicide. Indeed, specific sleep disorders and circadian rhythm disorders have been associated to suicidal behaviors, and the most replicated findings are insomnia and nightmares. Nevertheless, these interesting preliminary studies did not examine the chronology and trajectories of these dream...
European Psychiatry
March 1, 2023
M. C. Q. Lin, H. Lee, V.-W.-L. Tsang et al.
Introduction Despite emerging evidence suggesting the efficacy of psilocybin in the treatment of mood disorders such as depression, the exact mechanisms by which psilocybin is able to elicit these antidepressant effects remains unknown. Objectives As the use of psilocybin as a treatment modality for depression has garnered increasing interest, this study aims to summarize the existing evidence...
European Psychiatry
March 1, 2023
Ali Kandeğer, Şerife Odabaş Ünal, M. T. Ergün
Introduction: Excessive mind wandering is a common feature of ADHD in adulthood also referred to as mental restlessness and ceaseless mental overactivity. ADHD is a predisposing factor for many psychiatric symptoms, especially negative emotions such as depression and anxiety. Rumination is thought to be a mediator for depression in individuals with ADHD. The above-mentioned mental processes may...
JAAPA
March 1, 2023
Amber Teigen
ABSTRACT: Increasing incidence and survival rates of prostate cancer are leaving more men to suffer the sequelae of their diagnosis and treatment, like depression. Depression and other negative psychosocial factors significantly affect this population but often go undiagnosed and/or ineffectively managed. This case report focuses on the negative effects of prostate cancer diagnosis and...
Journal of Psychiatric Research
March 1, 2023
Mu-Hong Chen, T. Su, Li-Fen Chen et al.
BACKGROUND Whether cortical excitation and inhibition functions differ between patients with treatment-resistant depression (TRD) and strong suicidal ideation (SI) and healthy subjects and whether 0.5 mg/kg ketamine infusion can modulate cortical excitation and inhibition functions among patients with TRD-SI remain unclear. METHODS A total of 29 patients with TRD-SI and 35 age- and sex-matched...
European Psychiatry
March 1, 2023
Erhan Kavakbasi, Bernhard T Baune
IntroductionNMDA-Receptor antagonists have rapid antidepressant and antisuicidal properties. However, the antidepressant effect is short lasting raising the question of best maintenance strategy, which is unanswered so far. Invasive vagus nerve stimulation (VNS) as a treatment option for refractory and chronic major depression was shown to reduce the need of maintenance treatment sessions in...
Medicine
March 1, 2023
Wei Wang, Bin Ling, Qian Chen et al.
Background: To evaluate the effect of pre-administration of esketamine intraoperatively on the occurrence of postpartum depression after cesarean section under combined spinal-epidural anesthesia. Methods: A total of 120 women aged 24 to 36 years undergoing cesarean section by spinal-epidural anesthesia with American Society of Anesthesiologists physical status II were enrolled. According to...
Experimental and therapeutic medicine
March 2023
Octavian Vasiliu
Treatment-resistant depression (TRD) is a challenge for psychiatrists, even after more than seven decades since the first antidepressants were used in clinical practice. Non-monoaminergic-based drugs with antidepressant properties have been developed, but to date, only esketamine and brexanolone have been approved for TRD and postpartum depression, respectively. A narrative review on the...
PubMed Central
March 1, 2023
INTRODUCTION: Treatment resistant depression (TRD) is estimated to affect 10–30% of patients with major depressive disorder (Al‑Harbi et al. Patient Prefer Adherence 2012; 6 369–88). Esketamine nasal spray (NS), in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI), increases remission and response rates in patients with TRD...
Journal of geriatric psychiatry and neurology
March 2023
Alejandro Interian, Rachael B Miller, Lauren M St Hill et al.
Introduction: Parkinson's disease (PD) is characterized by high-rates of depression with limited evidence-based treatment options to improve mood. Objective: To expand therapeutic options, we evaluated the feasibility and effect of a telehealth mindfulness-based cognitive therapy intervention adapted for PD (MBCT-PD) in a sample of participants with DSM-5 depressive disorders. Methods: Fifteen...
Complementary Therapies in Medicine
March 1, 2023
Helena Schmidt, Christian Pilat
Low back pain (LBP) is a common biopsychosocial health problem. Meditation may provide a complementary treatment option for LBP patients. The aim of this systematic review with meta-analysis was to examine the effects of meditation on pain intensity, functional disability, quality of life, and depression in LBP populations. This systematic review was conducted according to the PRISMA...
Clinical Case Reports
March 1, 2023
Bruno Pedraz-Petrozzi, Michael Deuschle, Maria Gilles
We admitted a 42-year-old patient with severe treatment-resistant depression and with psychiatric comorbidities. The patient attempted suicide 5 weeks after admission. Subsequently, we initiated dextromethorphan/bupropion based on prior evidence. As a result, the patient demonstrated an improvement in mood symptoms and a reduction in suicide risk, leading to her discharge.
Expert Review of Neurotherapeutics
March 1, 2023
Zamfira Parincu, Dan V. Iosifescu
Major depressive disorder (MDD) is one of the leading causes of disability worldwide. However, many patients do not achieve an adequate clinical improvement with pharmacotherapies targeting monoamine receptors, and the onset of therapeutic benefit typically lags by 4-6 weeks. There is a significant need for mechanistically novel treatments with more rapid efficacy. Combinations of...
Journal of Affective Disorders
March 1, 2023
Debora de A. Simoes Moreira, Luís Eduardo Gauer, Guilherme Teixeira et al.
25 citations
Background: ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcomes (PROSPERO/CRD42022349220). Methods: We searched MEDLINE, Web of Science, Embase,...
European Psychiatry
March 1, 2023
K. P. Kuypers
2 citations
Abstract Decades ago, the classical psychedelics psilocybin and LSD entered the therapeutic setting and already then showed their therapeutic potential in the treatment of psychiatric disorders. For thousands of years another psychedelic, ayahuasca, is being used by tribes in western Amazonia for healing and divination, and in recent years its use has expanded worldwide. Research into the...
European Psychiatry
March 1, 2023
J. Ramírez González, I. Fernández Márquez, Serafín González et al.
Introduction The use of hallucinogens has accompanied the human being throughout history. In the 1970s, studies focused on the therapeutic potential of hallucinogens were blocked due to their misuse in the young population. At present, psilocybin is re-emerging as the center of attention due to its possible therapeutic potential in different psychiatric pathologies such as depression, anxiety...
European Psychiatry
March 1, 2023
Guy M. Goodwin, Lindsey Marwood, Sunil Mistry et al.
1 citation
Introduction COMP360 is a synthetic, proprietary, purified form of psilocybin in development for treatment-resistant depression (TRD) with FDA Breakthrough Therapy designation. In a recent phase IIb study, COMP360 psilocybin 25mg was superior to 1mg on change from baseline (CFB) to Week 3 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score (primary efficacy endpoint), when...
Journal of Psychopharmacology
March 1, 2023
Takesha Cooper, Michael David Seigler, Stephen M Stahl
18 citations
Numerous new agents with rapid onset antidepressant effects are entering clinical trials and clinical practice. Studies focus on either first-line treatment of major depressive disorder or on patients whose major depressive disorder is resistant to prior antidepressant drugs. Novel agents target three very different central nervous system sites: as antagonists of N-methyl-d-aspartate (NMDA)...